Abbott Laboratories (ABT) reports robust sales growth and improved margins, setting the stage for continued success in 2025 ...

Abbott Laboratories (NYSE: NYSE:ABT) has demonstrated resilience and growth potential in the healthcare sector, maintaining a strong financial profile despite facing various challenges. According to ...

The outlook and technical action suggest Abbott Laboratories (NYSE: ABT) will lead healthcare names like Johnson & Johnson ...

Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose ...

Today we’ll talk about two dividend growers that have serious upside. Each returned triple digits during Trump 1.0 and could ...

The global point of care diagnostics market valued at US$ 14.26 billion in 2023, is forecasted to grow at a robust CAGR of ...

Abbott reported $9.34 billion in diagnostics revenues in 2024, down 7 percent on a reported basis from $9.99 billion in 2023 and down 4 percent on an organic basis. Excluding COVID-19 testing-related ...

For the full calendar of 2024, Abbott recorded sales of $41.95 billion, following the launches last year of a new heart valve ...

Excluding COVID-19 testing-related sales, growth in Rapid Diagnostics was driven by strong demand for Abbott’s portfolio of respiratory disease tests. Guidance: Abbott projects full-year 2025 ...

The global point of care diagnostics market valued at US$ 14.26 billion in 2023, is forecasted to grow at a robust CAGR of 8.5%, reaching US$ ...

Excluding COVID-19 testing-related sales, growth in Rapid Diagnostics was driven by strong demand for Abbott’s portfolio of respiratory disease tests. Guidance: Abbott projects full-year 2025 adjusted ...